These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 20651367)
1. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats. Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367 [TBL] [Abstract][Full Text] [Related]
2. Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats. Laznicek M; Laznickova A; Mäcke HR; Eisenwiener K; Reubi JC; Wenger S Cancer Biother Radiopharm; 2002 Oct; 17(5):527-33. PubMed ID: 12470422 [TBL] [Abstract][Full Text] [Related]
3. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Trejtnar F; Laznicek M; Laznickova A; Kopecky M; Petrik M; Béhé M; Schmidt J; Maecke H; Maina T; Nock B Anticancer Res; 2007; 27(2):907-12. PubMed ID: 17465219 [TBL] [Abstract][Full Text] [Related]
4. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. Konijnenberg MW; Bijster M; Krenning EP; De Jong M J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541 [TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111. Trejtnar F; Novy Z; Petrik M; Laznickova A; Melicharova L; Vankova M; Laznicek M Ann Nucl Med; 2008 Dec; 22(10):859-67. PubMed ID: 19142704 [TBL] [Abstract][Full Text] [Related]
7. Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney. Laznicek M; Laznickova A Anticancer Res; 2012 Mar; 32(3):815-22. PubMed ID: 22399599 [TBL] [Abstract][Full Text] [Related]
8. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083 [TBL] [Abstract][Full Text] [Related]
9. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats. Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325 [TBL] [Abstract][Full Text] [Related]
10. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo. Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394 [TBL] [Abstract][Full Text] [Related]
13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800 [TBL] [Abstract][Full Text] [Related]
14. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472 [TBL] [Abstract][Full Text] [Related]
15. Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota. Försterová M; Petrík M; Láznicková A; Láznícek M; Hermann P; Lukes I; Melichar F Appl Radiat Isot; 2009 Jan; 67(1):21-9. PubMed ID: 18951809 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971 [TBL] [Abstract][Full Text] [Related]
17. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040 [TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver. de Jong M; Bakker WH; Breeman WA; van der Pluijm ME; Kooij PP; Visser TJ; Docter R; Krenning EP J Nucl Med; 1993 Nov; 34(11):2025-30. PubMed ID: 8229254 [TBL] [Abstract][Full Text] [Related]
19. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158 [TBL] [Abstract][Full Text] [Related]
20. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Lewis JS; Laforest R; Lewis MR; Anderson CJ Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]